Guillain-Barré Syndrome Following Zika Virus Infection Is Associated With a Diverse Spectrum of Peripheral Nerve Reactive Antibodies
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received December 5, 2022
- Accepted in final form September 1, 2022
- First Published November 21, 2022.
Author Disclosures
- Alexander J. Davies, PhD*,
- Cinta Lleixà, PhD*,
- Ana M. Siles, PhD,
- Dawn S. Gourlay, BSc,
- Georgina Berridge, BSc,
- Wanwisa Dejnirattisai, PhD,
- Carolina Ramírez-Santana, PhD,
- Juan-Manuel Anaya, MD, PhD,
- Andrew K. Falconar, PhD,
- Claudia M. Romero-Vivas, PhD,
- Lyda Osorio, MD, PhD,
- Beatriz Parra, PhD,
- Gavin R. Screaton, DPhil, FMedSci,
- Juthathip Mongkolsapaya, DPhil,
- Roman Fischer, PhD,
- Carlos A. Pardo, MD,
- Susan K. Halstead, PhD,
- Hugh J. Willison, MD, PhD,
- Luis Querol, MD, PhD† and
- Simon Rinaldi, MBChB, PhD†
- Alexander J. Davies, PhD*,
None
NONE
International Association for the Study of Pain, conference attendance financial aid (2018).Biolegend, Travel grant (2019).Korean Association of Immunologists, speaker honoraria (2019).
Frontiers in Cellular Neuroscience, Guest Editor, 2020.
Named on patent application for the use of immune therapy for nerve injury.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Cinta Lleixà, PhD*,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Ana M. Siles, PhD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Dawn S. Gourlay, BSc,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Georgina Berridge, BSc,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Wanwisa Dejnirattisai, PhD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Carolina Ramírez-Santana, PhD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Juan-Manuel Anaya, MD, PhD,
None
NONE
None
BMC Medicine, Editorial Board, since 2014
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Colciencias and Fundación para la promoción de la Investigación y la Tecnología del Banco de la República, Bogota, Colombia.
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Andrew K. Falconar, PhD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Claudia M. Romero-Vivas, PhD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Lyda Osorio, MD, PhD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Beatriz Parra, PhD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Gavin R. Screaton, DPhil, FMedSci,
1. GSK vaccines SAB
NONE
None
NONE
1. Dengue virus mAb and vaccine patents2. SARS-CoV-2 mAb patents
NONE
NONE
1. RQ Bio2. AstraZeneca
NONE
NONE
NONE
NONE
NONE
NONE
Wellcome TrustSchmidt FuturesRed Avenue FoundationOak Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Juthathip Mongkolsapaya, DPhil,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Roman Fischer, PhD,
None
NONE
None
NONE
NONE
NONE
NONE
1. University Of Oxford, Chemistry Depatment, Best practice on running an Orbitrap mass spectrometer
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Carlos A. Pardo, MD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NIH 1R01HL130649-01 Role: Co-Investigator 2015-2019R01 NS110122-01A1 Role: Principal Investigator, 2019-2024U01CA230691, Role: Co-Investigator, 2018-2023NIH/NCI R01CA230285, Role: Co-Investigator, 2019-2024
NONE
Bart McLean Fund for Neuroimmunology Research-Project RestoreSiegel Rare Neuroimmune Association
NONE
NONE
NONE
NONE
NONE
NONE
- Susan K. Halstead, PhD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Hugh J. Willison, MD, PhD,
(1) Annexon Inc SAB(2) Boehringer-Mannheim SMB(3) Roche SAB(4) GSK SAB(5) Polyneuron SAB(6) Janssen SMB(7) Hannsen AB(8) Immunic AG SAB(9) GeneTx Bio SMB
NONE
None
Current Editorial Board Member of Journals: Muscle and Nerve
NONE
NONE
NONE
(1) Argenx BVBA/SE, (2) Annexon Inc, (3) GlaxoSMithKine, (4) Janssen NL, (5) UCB Pharma(6) Hansa Medical AB(7) Astra-Zeneca
NONE
NONE
NONE
(1) Argenx SE(2) Polyneuron Pharma AG
(1) European Union
NONE
(1) The Wellcome Trust
(1) Annexon Inc
NONE
NONE
NONE
NONE
NONE
- Luis Querol, MD, PhD† and
Commercial entity: Sanofi-Genzyme, CSL Bering, Novartis, UCB Pharma, Janssen, Annexon, ArgenX, Merck, Octapharma,Alnylam, Takeda and Roche
NONE
Commercial: CSL Behring, Novartis, Roche and Biogen, travel grant.
Editorial Board Member of the European Journal of Neurology and Journal of the Peripheral Nervous System
NONE
NONE
NONE
NONE
Commercial: CSL Behring, Roche, Sanofi-Genzyme, Grifols, Merck, Novartis, Takeda, Akcea, LFB, and Biogen
NONE
NONE
Grifols, UCB
(1) Fondo de Investigaciones Sanitarias, PI19/01407(2) ACCI 2019-30 CIBERER(3) Fondo de Investigaciones Sanitarias, INT20/00080
NONE
GBS-CIDP Foundation International
NONE
NONE
NONE
NONE
NONE
NONE
- Simon Rinaldi, MBChB, PhD†
(1) Argenx advisory board
NONE
(1) PNS (non-proft), funding for travel and accommodation at international meeting
NONE
NONE
NONE
NONE
(1) Argenx advisory board
NONE
NONE
NONE
NONE
(1) Medical Research Council (UK), MR/P008399/1, 2017-2021, PI
NONE
(1) British Medical Association
NONE
NONE
NONE
NONE
NONE
NONE
- From the Nuffield Department of Clinical Neurosciences (A.J.D., S.R.), University of Oxford, John Radcliffe Hospital, UK; Neuromuscular Diseases Unit (C.L., A.M.S., L.Q.), Neurology Department, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Spain; Centro para la Investigación Biomédica en red en Enfermedades Raras–(CIBERER) Madrid (C.L., A.M.S., L.Q.), Spain; Institute of Infection (D.S.G., S.K.H., H.J.W.), Immunity & Inflammation, University of Glasgow, University Place, UK; Target Discovery Institute (G.B., R.F.), NDM Research Building, University of Oxford, Old Road Campus, UK; Wellcome Centre for Human Genetics (W.D., G.R.S., J.M.), Nuffield Department of Medicine, University of Oxford, UK; Center for Autoimmune Diseases Research (CREA) (C.R.-S., J.-M.A.), Universidad del Rosario, Bogotá, Colombia; Departamento de Medicina (A.K.F., C.M.R.-V.), Universidad del Norte, Barranquilla, Colombia; Grupo de Epidemiología y Salud Poblacional (GESP) (L.O.,), School of Public Health, Universidad del Valle, Cali, Colombia; Department of Microbiology (B.P.), School of Basic Sciences, Universidad del Valle, Cali, Colombia; Dengue Hemorrhagic Fever Research Unit (J.M.), Office for Research and Development, Siriraj Hospital, Faculty of Medicine, Mahidol Univeristy, Bangkok, Thailand; Department of Neurology (C.A.P.), Johns Hopkins University School of Medicine, Baltimore, MD; and LifeFactors (J.-M.A.), Rionegro, Colombia; Division of Emerging Infectious Disease (W.D.), Research Department, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
- Correspondence
Dr. Rinaldi simon.rinaldi{at}nhs.net
Article usage
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Daniel Friedman and Dr. Sharon Chiang
► Watch
Related Articles
- No related articles found.